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Previous trials prove the great negative influence of pain on health and patients'
quality of life. Some authors believe in the existence of similarities between
human and animal oncological pain. However, there is a lack of knowledge about
incidence and features of cancer-related pain in animals, as well as a non-
evaluation of oncologic pain and probably a consequent insufficient treatment.
MATERIAL AND METHODS
HRQoL and CBPI facilitate communication between owner and veterinarian, increase the possibility of detecting treatment adverse effects and changes
in patient's condition. However they are more focused on the assessment of disease and treatment than on pain evaluation. So in the future,
adaptations giving more value to pain questions and quantitative sensory test inclusions may improve their precision.
Further research is needed to improve oncological canine pain knowledge. Next studies should include a larger number of patients, discrimination by
tumor location and complete follow-up.
INTRODUCTION
ASSESSMENT OF ONCOLOGICAL PAIN IN CANINE SPECIES
OBJECTIVES
DISCUSSION AND CONCLUSIONS
1. Evaluate pain’s severity, functional impact and quality of life in canine cancer
patients of the UAB Veterinary Clinical Hospital (HCV-UAB).
2. Analyze the evolution of the studied parameters throughout the treatment
and assess if the analgesia received was effective.
3. Evaluate the usefulness of Health-Related Quality-of-Life Questionnaire
(HRQoL), Canine Brief Pain Index (CPBI) and Numeric pain Rating Scale (NRS).
Improve the method using previous human medicine studies.
 31% of patients with scores above 10
points Insufficient analgesia.
 Statistically significant differences between
os-sarcomas and lymphomas.
 The worst functionality appears in patients
with higher pain intensity or osteoarthritis.
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Quality of life (HRQoL and CPBI)NRS clinic-owner
 Very good correlation.
 Owners’ overall scores slightly higher
Functionality (CBPI) 
 Worse in tumor recurrence, only
palliative analgesia and aggressive
neoplasms  vocalizations and
general state altered.




Weak opioid ± Nonopioid ±adjuvant (5)
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Figure 1: Pain intensity in function of tumor histopathology (mean
±SD). Range: 0=no pain, 40=extreme pain
Figure 2: Functionality affect depending on tumor histopathology
(mean ±SD). Range: 0=no interference; 60=completely interferes.
Figure 3:Global quality of life
Figure 4: Correlation between clinic and owner NRS
score
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